CEACAM1 as a central modulator of metabolism, tumor progression, angiogenesis and immunity

被引:9
|
作者
Nouvion, Anne-Laure [1 ]
Beauchemin, Nicole [1 ,2 ,3 ,4 ]
机构
[1] McGill Univ, Ctr Cancerol McGill, Montreal, PQ H3G 1Y6, Canada
[2] McGill Univ, Dept Biochim, Montreal, PQ H3G 1Y6, Canada
[3] McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada
[4] McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada
来源
M S-MEDECINE SCIENCES | 2009年 / 25卷 / 03期
关键词
CELL-ADHESION MOLECULE-1; INSULIN; GROWTH; INHIBITION; MECHANISM; MIGRATION; MELANOMA; INVASION;
D O I
10.1051/medsci/2009253247
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
CEACAM1 (carcinoembryonic antigen cell adhesion molecule 1), a member of the immunoglobulin (1g) superfamily, is a heavily glycosylated protein. This glycoprotein exhibits an intracytoplasmic region that can be either long (71-73 amino acids) with two inhibitory tyrosine-phosphorylated motifs and several phosphorylated serine residues, or short (10 amino acid). CEACAM1 is a multifunctional protein that plays a role in intercellular adhesion, as an inhibitor of tumor development, as a bacterial adhesin, and as a receptor for the mouse hepatitis virus. Moreover, CEACAM1 is an active regulator of cell signaling, modulating the insulin or EGF receptor pathways in epithelial cells or the Zap-70 pathway in hematopoietic cells. The recent development of genetically modified mouse models altering the Ceacam1 gene corroborates most of these data, but also highlights CEACAM1's functional complexity. Thus, in addition to the functions identified previously, CEACAM1 is an important regulator of lipid metabolism, of tumor progression as a regulator of the Wnt signaling pathway, of normal and tumor neoangiogenesis and of immunity. lozenge
引用
收藏
页码:247 / 252
页数:6
相关论文
共 50 条
  • [1] Inhibition of prostate tumor angiogenesis by the tumor suppressor CEACAM1
    Volpert, O
    Luo, WP
    Liu, TJ
    Estrera, VT
    Logothetis, C
    Lin, SH
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (38) : 35696 - 35702
  • [2] Tumor angiogenesis regulation in prostate cancer by CEACAM1
    Tilki, Derya
    Oliveira-Ferrer, Leticia
    Seitz, Michael
    Friedrich, Martin G.
    Stief, Christian G.
    Ergun, Suleyman
    JOURNAL OF UROLOGY, 2008, 179 (04): : 419 - 419
  • [3] Tumor Angiogenesis Mediated by Myeloid Cells Is Negatively Regulated by CEACAM1
    Lu, Rongze
    Kujawski, Maciej
    Pan, Hao
    Shively, John E.
    CANCER RESEARCH, 2012, 72 (09) : 2239 - 2250
  • [4] Epithelial Versus Endothelial CEACAM1 Expression and Angiogenesis in Epididymal Adenomatoid Tumor
    Kilic, Nerbil
    Tilki, Derya
    Erguen, Babek
    Seitz, Michael
    Stief, Christian G.
    Reich, Oliver
    Erguen, Sueleyman
    ANTICANCER RESEARCH, 2010, 30 (07) : 2651 - 2657
  • [5] NB203: A Novel therapeutic bispecific antibody targeting CEACAM1/VEGF for tumor immunity and angiogenesis modulation in the tumor microenvironment
    Dong, Jinyu
    Wang, Binbin
    Wang, Dong
    Ni, Jie
    Bu, Tingting
    Wang, Haojie
    Nayak, Bishnu
    Wang, Baiyang
    Dong, Xin
    Zhang, Yu
    CANCER RESEARCH, 2024, 84 (06)
  • [6] Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1
    Gur, Chamutal
    Maalouf, Naseem
    Shhadeh, Amjad
    Berhani, Orit
    Singer, Bernhard B.
    Bachrach, Gilad
    Mandelboim, Ofer
    ONCOIMMUNOLOGY, 2019, 8 (06):
  • [7] CEACAM1: contact-dependent control of immunity
    Gray-Owen, Scott D.
    Blumberg, Richard S.
    NATURE REVIEWS IMMUNOLOGY, 2006, 6 (06) : 433 - 446
  • [8] CEACAM1: contact-dependent control of immunity
    Scott D. Gray-Owen
    Richard S. Blumberg
    Nature Reviews Immunology, 2006, 6 : 433 - 446
  • [9] CEACAM1 structure and function in immunity and its therapeutic implications
    Kim, Walter M.
    Huang, Yu-Hwa
    Gandhi, Amit
    Blumberg, Richard S.
    SEMINARS IN IMMUNOLOGY, 2019, 42
  • [10] The expression and modulation of CEACAM1 and tumor cell transformation
    Fiori, Valentina
    Magnani, Mauro
    Cianfriglia, Maurizio
    ANNALI DELL ISTITUTO SUPERIORE DI SANITA, 2012, 48 (02): : 161 - 171